Vaccine effectiveness against influenza A-associated hospitalization, organ failure, and death: United States, 2022-2023

Nathaniel M Lewis
Centers for Disease Control and Prevention

Jennie H Kwon
Washington University School of Medicine in St. Louis

et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/oa_4/3678

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023

Background. Influenza circulation during the 2022–2023 season in the United States largely returned to pre–coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. Influenza A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b, a close antigenic match to the vaccine strain.

Methods. To understand effectiveness of the 2022–2023 influenza vaccine against influenza-associated hospitalization, organ failure, and death, a multicenter sentinel surveillance network in the United States prospectively enrolled adults hospitalized with acute respiratory illness between 1 October 2022, and 28 February 2023. Using the test-negative design, vaccine effectiveness (VE) estimates against influenza-associated hospitalization, organ failures, and death were measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2–negative control-patients.

Results. A total of 3707 patients, including 714 influenza cases (33% vaccinated) and 2993 influenza- and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–negative controls (49% vaccinated) were analyzed. VE against influenza-associated hospitalization was 37% (95% confidence interval [CI]: 27%–46%) and varied by age (18–64 years: 47% [30%–60%]; ≥65 years: 28% [10%–43%]), and virus (A[H3N2]: 29% [6%–46%], A[H1N1]: 47% [23%–64%]). VE against more severe influenza-associated outcomes included: 41% (29%–50%) against influenza with hypoxemia treated with supplemental oxygen; 65% (56%–72%) against influenza with respiratory, cardiovascular, or renal failure treated with organ support; and 66% (40%–81%) against influenza with respiratory failure treated with invasive mechanical ventilation.

Conclusions. During an early 2022–2023 influenza season with a well-matched influenza vaccine, vaccination was associated with reduced risk of influenza-associated hospitalization and organ failure.

Keywords. influenza; vaccine effectiveness; attenuation; organ failure; acute respiratory illness.
The adoption of non-pharmaceutical interventions intended to reduce the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (eg, masking, social distancing) during the coronavirus disease 2019 (COVID-19) pandemic likely contributed to the low influenza circulation observed during the 2020–2021 and 2021–2022 seasons [1]. Influenza vaccine effectiveness (VE) was low during the 2021–2022 season, during which influenza A(H3N2) viruses predominated. Although interim and mid-season VE estimates for 2021–2022 showed almost no effectiveness against influenza virus infection in outpatient settings [2, 3], end-of-year estimates showed some protection against influenza-associated hospitalization for adults aged <65 years without immunocompromising conditions [4]. The 2022–2023 season in the United States was early compared with past seasons, beginning in October 2022 and peaking in December 2022, and marked a return to influenza circulation consistent with influenza seasons prior to the COVID-19 pandemic [1, 5, 6].

Viruses belonging to the influenza A(H3N2) 3C.2a1b.2a clade predominated during the 2022–2023 season, accounting for about two-thirds of influenza cases, followed by those from the influenza A(H1N1)pdm09 virus 6B.1A.5a clade [1]. The 2022–2023 influenza vaccine matched these 2 viruses well; it contained an influenza A/Darwin/9/2021 (H3N2)-like virus, similar to the influenza A(H3N2) 3C.2a1b.2a clade, and an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus, similar to the influenza A(H1N1) 6B.1A.5a clade [7, 8]. With notable exceptions [9–11], few studies have measured VE against severe outcomes in hospitalized or severely ill patients. Data on the effectiveness of the 2022–2023 influenza vaccine for preventing the full spectrum of influenza-associated severe disease are therefore useful.

The Investigating Respiratory Viruses in the Acutely Ill (IVY) Network is a multistate network of hospitals in the United States that enrolls adults hospitalized with acute respiratory illness (ARI) to evaluate the effectiveness of respiratory virus vaccines [12–14]. The objectives of this analysis were to evaluate the effectiveness of the 2022–2023 influenza vaccine against influenza-associated hospitalization, organ failures, and death.

METHODS

Participants and Sites

Twenty-four hospitals from 19 US states within the IVY Network prospectively enrolled patients into this multipathogen ARI surveillance program between 1 October 2022, and 28 February 2023 (Appendix A). The IVY Network is funded by the Centers for Disease Control and Prevention (CDC) and coordinated from Vanderbilt University Medical Center. This program was determined to be a non-research public health surveillance activity by CDC and each participating site and was conducted in a manner consistent with applicable federal law and CDC policy.

Personnel at all sites were trained to follow a common protocol outlining eligibility criteria, data collection, and specimen collection procedures. Patient eligibility criteria included: (1) age ≥18 years; (2) hospital admission; (3) clinical presentation consistent with ARI, defined as having ≥1 of the following: fever, cough, shortness of breath, new hypoxemia, or new pulmonary findings on chest imaging consistent with pneumonia; and (4) a clinically obtained molecular or antigen test for influenza virus, SARS-CoV-2, or respiratory syncytial virus (RSV) within 10 days of symptom onset (Appendix B, section 1).

For this analysis, patients who tested positive for influenza were classified as cases; those who tested negative for influenza and SARS-CoV-2 were classified as controls. Site personnel attempted to enroll all eligible influenza, SARS-CoV-2, and RSV cases and enrolled eligible controls in a 1:1 ratio with locally enrolled cases. Controls were enrolled within 2 weeks of a corresponding case.

Centralized Viral Testing

In addition to local clinical viral testing, upper respiratory specimens were collected from participants at enrollment and shipped to Vanderbilt University Medical Center (Nashville, Tennessee, USA) for centralized reverse transcription–polymerase chain reaction (RT-PCR) testing for influenza virus, SARS-CoV-2, and RSV using a standardized process (Appendix B, section 2) [12]. Influenza cases tested positive for influenza virus and negative for SARS-CoV-2 by local clinical testing and/or centralized RT-PCR testing. Controls, however, had to test negative for both influenza virus and SARS-CoV-2 by all completed clinical tests and centralized tests. Specimens that tested positive for influenza virus by RT-PCR at the central laboratory underwent viral whole genome sequencing at University of Michigan (Ann Arbor, Michigan, USA) (Appendix B, section 2).

Influenza Vaccination Status Ascertainment

Current-season influenza vaccination status was determined by electronic medical record and local Immunization Information System (IIS) searches and by plausible self-report that included the date and location of vaccine receipt (Appendix B, section 3) [15]. A patient was classified as vaccinated if they received ≥1 influenza vaccination on or after 1 August 2022, and at least 14 days before illness onset. Patients were classified as unvaccinated if they received no influenza vaccine doses between 1 August 2022, and the date of illness onset. Data on vaccinations during previous seasons were not collected.

Outcomes

The primary outcome for evaluation of influenza vaccine effectiveness was influenza-associated hospitalization, defined as
hospital admission for symptomatic, laboratory-confirmed influenza virus infection. Vaccine effectiveness against more severe influenza-associated disease was assessed using secondary outcomes of symptomatic, laboratory-confirmed influenza with: (1) hypoxemia treated with supplemental oxygen therapy at any flow rate or by any device; (2) acute respiratory, cardiovascular or renal failure treated with organ support (a composite of new receipt of high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, vasopressor use, or renal replacement therapy); (3) respiratory failure treated with invasive mechanical ventilation; (4) intensive care unit (ICU) admission; and (5) death (detailed definitions of each in Appendix B, section 4).

Analytical Exclusions
The analysis excluded enrolled patients who: (1) were identified as not meeting eligibility criteria; (2) tested positive for SARS-CoV-2; (3) were enrolled as controls before the first influenza case or after the last influenza case at the local site (which ensured all included controls were enrolled during local circulation of influenza); (4) had unknown influenza vaccination status; or (5) were missing data required for the VE against influenza-associated hospitalization model. Patients with SARS-CoV-2 infection were not included as controls in this analysis due to potential confounding stemming from an association between influenza and COVID-19 vaccine receipt and consequent downward bias on influenza VE estimates [16, 17]; recent analysis from our network estimated VE to be 7 percentage points lower with the inclusion of SARS-CoV-2-positive controls than without [4].

Statistical Analysis
We described demographic and clinical characteristics of influenza case-patients and control-patients, as well as vaccinated and unvaccinated patients, using counts and percentages or medians and interquartile ranges. Case versus control and vaccinated versus unvaccinated groups were compared using the Pearson $\chi^2$ test for categorical variables or Wilcoxon rank-sum testing for continuous variables.

Consistent with a test negative design for evaluation of vaccine effectiveness [18–20], logistic regression was used to calculate the odds of vaccination (vaccinated vs unvaccinated status) among cases with the outcomes of interest (the primary outcome and each secondary outcome) versus controls. Logistic regression models were adjusted for potential confounders, including age (continuous, in years); sex (male/female), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Other, Unknown), Census region, month/year of enrollment, number of categories of medical comorbidities (0, 1, 2, 3, $\geq$4), and the following yes/no variables: residence in a long-term care facility, hospital admission in the last year and immunocompromised status (Appendix B, section 5). Vaccine effectiveness for protection against the outcome of interest was then calculated as: $(1 - \text{adjusted odds ratio for vaccination}) \times 100\%$.

VE against influenza-associated hospitalization (primary outcome) was calculated for the overall population, patient age groups (18–64 years; $\geq$65 years), immunocompromised status (immunocompetent; immunocompromised), and subtype of influenza virus (A[H3N2]; A[H1N1]). Immunocompromised status was classified based on the definition of moderate-to-severe immunosuppression by the National Institutes of Health (Appendix B, section 6) [21].

The proportions of patients experiencing each of the secondary severe outcomes were compared between vaccinated cases and unvaccinated cases using unadjusted $\chi^2$ tests. Additionally, peak severity of respiratory illness experienced during the first 28 days of hospital admission was classified by assigning each case to 1 of 5 ordinal categories based on the highest level of respiratory support received: (1) no supplemental oxygen; (2) standard flow supplemental oxygen (flow rate <30 liters/minute); (3) high-flow nasal cannula or non-invasive ventilation; (4) invasive mechanical ventilation; or (5) death. We developed a multivariable proportional odds regression model where vaccination status was the primary exposure variable, the five-category ordinal respiratory severity scale was the outcome variable, and the same covariates used in the VE models were included (Appendix B, section 5).

Finally, VE against each of the 5 secondary outcomes was calculated using the same approach described for VE against hospitalizations. Separate logistic regression models were constructed in which cases were defined as influenza patients who met each of the outcome definitions. The same control group (adults hospitalized with ARI and testing negative for influenza virus and SARS-CoV-2) were used in VE models for all outcomes. Analyses were conducted using R (Vienna, Austria) [22].

RESULTS
Enrollment and Patient Characteristics
Overall, 7129 patients were enrolled between 1 October 2022, and 28 February 2023. Of these, 3422 were excluded from the analysis, with the most common reasons being testing positive for SARS-CoV-2 (2496), incomplete data on influenza vaccination status (690), and enrollment as a control before the first or after the last influenza case at the local site (232) (Appendix C, Supplementary Figure 1). A total of 3707 patients comprised the analytic data set, including 714 influenza cases and 2993 controls.

Among 714 influenza-case patients, influenza type was determined by RT-PCR for 431 patients, including 286/431 (67%) with influenza A(H3N2) and 145/431 (33%) with influenza A(H1N1). Among the 286 patients with influenza A(H3N2) confirmed by RT-PCR, viral whole genome sequencing identified a clade in 219 patients, all of which were clade 3C.2a1b.2a.
Influenza A(H1N1) was detected in 145 patients, of which 100 were clade 6B.1A.5a.2, and no influenza B was detected.

Influenza vaccination was lower among influenza case patients (235/714; 33%) than control patients (1462/2993, 49%) (\(P < .001\)) (Table 1). Among vaccinated patients, case patients had shorter times from influenza vaccination to illness onset (median [interquartile range {IQR}]: 63 days [43–83 years]) compared with control patients (74.5 days [47–103 days], \(P < .001\)). Additionally, case patients, compared with control patients, were younger (median age: 63 vs 65 years, \(P = .006\)), more likely to be non-Hispanic Black (30% vs 23%; \(P < .001\)), and less likely to have had \(\geq 1\) hospitalization in the previous year (51% vs 62%, \(P < .001\)). Patients who received influenza vaccination, compared with unvaccinated patients, were older (median age: 68 vs 62 years, \(P < .001\)), more likely to be non-Hispanic White (65% vs 49%; \(P < .001\)), more likely to be immunocompromised (19% vs 14%; \(P < .001\)), and more likely to have had \(\geq 1\) hospitalization in the previous year (63% vs 57%; \(P < .001\)) (Appendix D, Supplementary Table 1).

### VE Against Influenza-associated Hospitalization

Overall, VE against influenza-associated hospitalization was 37% (95% confidence interval [CI]: 27%–46%) and was
similar among those vaccinated 14–90 days prior to illness onset (39% [95% CI: 29%–48%]) and those vaccinated >90 days before onset (39% [95% CI: 33%–61%]) (Figure 1). Stratified by age group, VE was 47% (95% CI: 30%–60%) among adults aged 18–64 years, and 28% (95% CI: 10%–43%) among adults aged ≥65 years. By immunocompromised status, VE was 35% (95% CI: 23%–45%) for immunocompetent patients and 49% (95% CI: 19%–68%) for immunocompromised patients; VE differed between immunocompetent adults aged 18–64 years (44% [95% CI: 25%–58%]) and aged ≥65 years (28% [95% CI: 28% [7%–45%]). Stratified by virus subtype, VE against influenza-associated hospitalization was 29% (95% CI: 6%–46%) for influenza A(H3N2) and 47% (95% CI: 23%–64%) for influenza A(H1N1). VE against influenza A(H3N2) differed between patients aged 18–64 years (56% [95% CI: 36%–72%]) and ≥65 years (7% [95% CI: −35% to 36%]).

### Illness Severity Among Vaccinated and Unvaccinated Influenza Cases

In unadjusted comparisons, a lower proportion of vaccinated cases compared with unvaccinated cases experienced many of the severe outcomes, including invasive mechanical ventilation (6% vs 11%, \( P = .03 \)), vasopressor use (5% vs 11%, \( P = .02 \)), organ support (15% vs 25%, \( P < .001 \)), and intensive care unit (ICU) admission (11% vs 22%, \( P < .001 \)) (Table 2). Based on a 5-category ordinal scale for respiratory disease severity, vaccinated cases had lower peak severity in the hospital compared with unvaccinated cases (adjusted odds ratio: 0.59 [95% CI: .50–.70]) (Figure 2).

### VE Against Organ Failure and Death Outcomes

Influenza vaccination demonstrated benefit against: influenza with hypoxemia treated with supplemental oxygen (VE: 41% [95% CI: 29%–50%]); influenza with respiratory, cardiovascular, or renal failure treated with acute organ support (VE: 65% [95% CI: 56%–72%]); influenza with respiratory failure treated with invasive mechanical ventilation (VE: 66% [95% CI: 40%–81%]); and influenza-associated ICU admission (VE: 69% [95% CI: 59%–83%]) (Figure 3). VE against influenza-associated death was 48% (95% CI: 70% to 84%); however, the number of influenza-associated deaths was limited (5 vaccinated and 12 unvaccinated influenza cases died), resulting in a wide confidence interval.

#### DISCUSSION

During the 2022–2023 US influenza season, we found significant VE against adult influenza-associated hospitalization overall and across subgroups based on age, immunocompromised status, and virus type. Furthermore, we found strong VE against severe manifestations of influenza, including organ failure, need for invasive mechanical ventilation, and ICU admission.

The VE against influenza-associated hospitalization reported here was higher than from the same network during the prior year (the 2021–2022 influenza season), when overall VE against hospitalization was 26% (95% CI: −14% to 52%) [4]. Higher VE during 2022–2023 compared with the 2021–2022 season may be attributable to the relative earliness of the 2022–2023 season, which peaked during early December 2022 with a hospitalization rate of about 9 per 100 000 [1]. In contrast, the largest peak for the 2021–2022 season occurred in early April 2022 (4 months later), with a hospitalization rate of about 2 per 100 000 [1]. Due to the early influenza season during 2022–2023, the median days from last vaccination to illness onset in this analysis was 72.5 days (IQR: 47–103 days) compared with 161 days (IQR: 122–196 days) during 2021–2022 in the same network [4]. Waning protection from influenza vaccination has been observed in previous seasons, particularly those with late onset and peaks [23]. Although this study found no difference in VE between patients vaccinated 14–90 versus ≥90 days before illness onset, it is possible that substantial waning does not begin until later (eg, 150 days), and few patients during the 2022–2023 season were vaccinated this long before

### Table 2. In-hospital Outcomes Through Hospital day 28 Among Patients Hospitalized With Influenza Infection (Cases), by Vaccination Status

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Vaccinated Cases (n = 235)</th>
<th>Unvaccinated Cases (n = 479)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplemental oxygen therapy (standard flow oxygen, high-flow nasal cannula, non-invasive ventilation, or invasive mechanical ventilation)</td>
<td>155 (66%)</td>
<td>319 (67%)</td>
<td>.93</td>
</tr>
<tr>
<td>High-flow nasal cannula and/or non-invasive ventilation</td>
<td>19 (8%)</td>
<td>61 (13%)</td>
<td>.08</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>14 (6%)</td>
<td>54 (11%)</td>
<td>.03</td>
</tr>
<tr>
<td>Acute vasopressor use</td>
<td>11 (5%)</td>
<td>49 (10%)</td>
<td>.02</td>
</tr>
<tr>
<td>Acute renal replacement therapy</td>
<td>0/226* (0%)</td>
<td>3/458* (1%)</td>
<td>.55</td>
</tr>
<tr>
<td>Acute organ support (high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, renal replacement therapy, or vasopressor use)</td>
<td>35 (15%)</td>
<td>122 (25%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Intensive care unit admission</td>
<td>27 (11%)</td>
<td>107 (22%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Death</td>
<td>5 (2%)</td>
<td>12 (3%)</td>
<td>.96</td>
</tr>
</tbody>
</table>

*Patients on chronic renal replacement therapy before their influenza illness were not eligible for acute renal replacement therapy and hence were removed from the denominator for this outcome. Chronic renal replacement therapy was received by 9 vaccinated cases and 21 unvaccinated cases.
illness onset. Although the early influenza season during 2022–2023 likely played a role in the relatively high observed VE during this year compared to prior years, low VE in many seasons suggests an ongoing need for improved influenza vaccines, including messenger RNA (mRNA) vaccines.

Influenza surveillance networks [1] and individual studies [5, 6], including the current analysis, found that influenza A(H1N1) comprised about one third of circulating viruses during an A(H3N2) predominant 2022–2023 season. As observed in this study, VE is typically higher for A(H1N1) than A(H3N2) viruses, which likely contributed to higher VE against influenza A during this season compared with prior seasons with lower proportions of A(H1N1) cases [8, 24, 25]. Lower VE against A(H3N2) may be due to mutations in A(H3N2) that result in escape of the virus from the immune response to vaccination [26, 27].

The lower VE observed for adults ≥65 years old, especially against A(H3N2), may be due to immunological factors in this subgroup [9, 10, 28, 29]. Adults ≥65 years old were not exposed to A(H3N2) early in life, potentially reducing the effectiveness of vaccination later in life against A(H3N2) via the phenomenon of immune imprinting. In this analysis A(H3N2) cases were slightly more frequent in patients aged ≥65 years compared with those aged 18–64 years (68% vs 65% of cases). Additionally, lower VE in older adults might be partially related to immune senescence [30], “inflamm-aging” (ie, a chronic low-level state of inflammation from multiple underlying conditions and frailty suspected

Figure 1. Vaccine effectiveness (VE) against influenza-associated hospitalization for the 2022–2023 seasonal influenza vaccine overall and by subgroups. Abbreviation: CI, confidence interval.

Figure 2. Peak respiratory illness severity experienced during the first 28 d of hospitalization among vaccinated and unvaccinated influenza cases. Peak respiratory illness severity was classified based on a 5-level scale, including: (1) no oxygen therapy; (2) standard flow supplemental oxygen (flow rate < 30 L/min); (3) high flow nasal cannula or non-invasive ventilation; (4) invasive mechanical ventilation; (5) death. Overall, vaccinated cases experienced lower peak severity than unvaccinated cases (adjusted odds ratio: 0.59 [95% CI: 0.50–0.70]). Abbreviation: CI, confidence interval.
to impair immune responses in older adults) [31], and potential blunting effects of repeated vaccination [32].

Interestingly, we found similar VE for immunocompromised and immunocompetent adults. Although lower VE against severe influenza in immunocompromised patients has been observed in previous studies [33], including within this network during prior years [4, 9], patients with immunocompromising conditions are a heterogenous group where varying composition from season to season may affect seasonal VE in the immunocompromised population compared to the concurrent immunocompetent population. A recent meta-analysis across multiple seasons found no difference in influenza VE between immunocompromised and immunocompetent persons [34], supporting that influenza VE may not be reduced in some immunocompromised populations. In addition, the potentially higher likelihood of both being vaccinated and being hospitalized with low-severity illness among immunocompromised patients could lead to residual confounding [35].

Importantly, influenza vaccination was associated with a beneficial effect even for patients hospitalized with influenza, as evidenced by better in-hospital outcomes among vaccinated compared with unvaccinated cases. These findings suggest that vaccination can attenuate influenza disease severity and prevent the most severe manifestations of influenza even in those infected despite vaccination. Our findings of substantial VE against influenza-associated ICU admission and a range of organ failures quantify the benefit of vaccination for the prevention of these severe outcomes.

This analysis was subject to limitations. First, sample size limited VE estimation or precision for some subgroups. Second, data on the type of influenza vaccine received were not collected, precluding comparative effectiveness analyses by vaccine type. Of note, most US adults aged ≥65 years receive a higher-dose or adjuvanted vaccine (compared with standard dose vaccine); thus, adverse biological and virological factors associated with influenza in older adults may offset the benefits of enhanced vaccines [35]. Third, the low number of influenza-associated deaths in this analysis limited our ability to make conclusions about VE against influenza-associated mortality. Finally, although the analysis controlled for several relevant potential confounders, residual confounding is possible.

CONCLUSIONS
During the 2022–2023 US influenza season, characterized by an early peak of influenza activity and a good match between the vaccine and circulating viruses, we observed significant protection from vaccination against influenza-associated hospitalizations overall, for both A(H3N2) and A(H1N1) subtypes, and for key patient subgroups at increased risk for severe illness, including those ≥65 years old and those with immunocompromising conditions. Substantial VE was observed against a range of severe influenza-associated outcomes, including organ failures and ICU admission, demonstrating that vaccination can be beneficial in preventing the most severe manifestations of influenza even when infection is not averted.

Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes

Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

Financial support. This work was supported by the US Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (contract numbers 75D3012C12914 and 75D3012C14944 to W. H. S.).

Potential conflicts of interest. S. R. reports participating as the DSMB chair for Hamilton Ventilators, outside the submitted work. J. C. reports receiving funding from the National Institutes of Health (NIH) and Department of Defense (DoD), and a travel grant from Fisher-Paykel, outside the submitted work. S. C. reports consulting for PureTech Health in 2021–2022 and Kiniksa Pharmaceuticals in 2022, outside the submitted work. A. D. reports participating on an advisory board for Alung Technologies and being a principal investigator (PI) for the PETAL Network, outside the submitted work. C. G. G. reports consulting fees from Merck and received research support from Campbell Alliance/Syneos Health, NIH, CDC, Food and Drug Administration (FDA), and AHRQ, outside the submitted work. M. N. G. reports receiving grant funding from NIH and AHRQ for research, honorarium for giving Medicine grand rounds at Yale and Washington Healthcare, fees for DSMB for Palm trial and Regeneron trials on monoclonal antibodies, and fees for serving on scientific advisory board for Philips Healthcare on monitoring, outside the submitted work. R. G. reports consulting for Gilead Sciences, Eli Lily, GSK, Janssen, and AbbVie, being on an advisory board for Gilead Sciences, Eli Lily, GlaxoSmithKline (GSK), and AstraZeneca, speaker bureau for Pfizer and AbbVie, and gift-in-kind to institution from Gilead Sciences, outside the submitted work. N. H. reports prior grant support from Sanofi and Quidel, and current funding from Merck, outside the submitted work. A. L. reports being a consultant for Roche on a clinical trial of baloxavir, outside the submitted work. Christopher Mallow reports medical legal consulting, outside the submitted work. I. P. reports receiving grants from NHLBI, NIGMS, and Janssen Pharmaceuticals and institutional support from Regeneron, outside the submitted work. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
